CHRONOS19: INTERIM ANALYSIS OF THE OBSERVATIONAL STUDY OF COVID-19 IN PATIENTS WITH BLOOD DISEASES

НАБЛЮДАТЕЛЬНОЕ ИССЛЕДОВАНИЕ У ПАЦИЕНТОВ С ЗАБОЛЕВАНИЯМИ СИСТЕМЫ КРОВИ И COVID-19 В РОССИИ
The emergence of a new infectious disease COVID-19 led to the extensive research of not only the coronavirus itself, but also the course of this disease in different patient populations. This is especially true for patients with a high risk of severe disease and mortality, in particular, those suffering from oncologic and hematologic diseases. In order to understand how COVID-19 develops in patients with hematologic (blood) diseases, a multicenter study CHRONOS19 was launched in June 2020 among patients with COVID-19 and hematologic diseases in Russia. The study was ...

Далее...


CHRONOS19 STUDY RECOGNIZED WITH THE AMERICAN SOCIETY OF HEMATOLOGY AWARD

The interim results of the observational study "Registry of Patients with Hematologic Disease and COVID-19 in Russia" will be presented at the 62nd annual meeting of the American Society of Hematology (ASH), which will be held on December 5-8 in a virtual format. A poster presentation is included in Session: 904. Outcomes Research — Non-Malignant Conditions. The research was recognized with the Abstract Achievement Award, which supports select trainees with high-achieving annual meeting abstracts who are chosen to present their work at the ASH annual meeting. The ...

Далее...


RAKFOND AT THE RUSSIAN ONCOLOGY CONGRESS

The XXIV Russian Oncology Congress opened on November 11, 2020, in a virtual format with a joint session of the Russian Society of Clinical Oncology (RUSSCO) and RakFond, dedicated to academic research that has changed clinical practice. During the session, leading experts in oncology and hematology from Russia and the United States discussed the role of research initiated by scientists and physicians in the advancement of oncology, opportunities and limitations, barriers in implementation, and steps towards conducting their own research projects. One-hundred and ...

Далее...


PLATINUM-BASED CHEMOTHERAPY IN TREATMENT OF PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER

Ovarian cancer is one of the most sensitive tumors to chemotherapy - in most cases it is possible to achieve complete tumor regression affected by modern drug treatment. Unfortunately, despite these successes, a large number of patients have developing relapses after the initial treatment, which entails the need for repeated chemotherapy. In recurrent ovarian cancer, current standards of therapy suggest treatment depending on the time elapsed since the completion of platinum-containing chemotherapy. In cases when less than 6 months have passed since the end of the ...

Далее...


Annual cancer progress report issued by the American association for cancer research

Turning science into lifesaving care The American Association for Cancer Research (AACR) released its annual Cancer Progress Report, which highlights advances over the past year in the prevention, detection, diagnosis, and treatment of cancer.  Below is a brief summary of this report. Cancer in 2020 In the United States, the overall cancer death rate has been steadily decreasing since the 1990s, with the reductions by 29 percent from 1991 to 2017 translating into more than 2.9 million cancer deaths avoided. The decline in the overall cancer death rate is being ...

Далее...


Nobel Prize 2020

The discoveries for which the Nobel Prize in Chemistry and Physiology or Medicine was awarded this year are significant for advances in oncology. This year’s Nobel Prize in Physiology or Medicine is awarded jointly to Harvey J. Alter, Michael Houghton, and Charles M. Rice for the discovery of Hepatitis C virus, a major global health problem that causes cirrhosis and liver cancer in people around the world. Prior to their work, the discovery of the Hepatitis A and B viruses had been critical steps forward, but the majority of blood-borne hepati...

Далее...


Highlights of 2020 ASCO Annual Meeting

This year the American Society of Clinical Oncology (ASCO) Annual Meeting was delivered in a new virtual format on May 29-31, 2020 with a record-breaking attendance of more than 42,700 participants from 138 countries. The scientific program comprised nearly 5,300 abstracts and more than 100 on-demand and broadcast sessions featuring more than 2,300 oral and poster presentations, a plenary session on the top five practice-changing studies, cancer-specific highlights sessions featuring the highest-impact studies in each area, and clinical cancer symposia. Here are highlig...

Далее...


The results of the research supported by the RakFond by Bulatov E.R.

Immunotherapy with genetically modified lymphocytes, such as CAR-T cells, is one of the most promising areas of modern basic and clinical oncology. A CAR-T cell is a T-lymphocyte in which a gene encoding a CAR (chimeric antigen receptor) has been introduced ex vivo. Simplifying the concept, one can say that a T cell is a soldier of the regular troops, and a CAR-T cell is the special forces for performing highly complex tasks. An extracellular domain of the CAR provides recognition of the target tumor antigen (e.g. CD19), and an intracellular domain activates the mechanisms ...

Далее...


Dear Friends and Colleagues! Today, on March 16, Professor Boris Afanasyev, member of the Foundation’s Scientific Advisory Board, Doctor of Medical Sciences, Honored Doctor of the Russian Federation, Director of the R.M. Gorbacheva Institute of Pediatric Oncology, Hematology, Oncology and Transplantology, founder of one of the first bone marrow transplant departments in the Russian Federation, suddenly passed away. His contribution to the oncology science is indisputable, he was an outstanding physician and the Teacher for many people. An amazing person, a unique ...

Далее...


RakFond Announces a New Competition of Research Projects in Radiation Therapy

Today, on World Cancer Day, the Foundation for Cancer Research Support opens applications submission to the competition of research projects in radiation therapy in oncology.

Далее...